Trial Profile
A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-alpha Therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Elan Pharmaceuticals
- 16 Oct 2009 New trial record.